Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma by Sonja Zweegman, Bronno van der Holt,

Slides:



Advertisements
Similar presentations
Palumbo A et al. Proc ASH 2013;Abstract 536.
Advertisements

Facon T et al. Proc ASH 2013;Abstract 2.
Ravi Vij MD Associate Professor Section of BMT and Leukemia
Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.
1. 2 Lenalidomide in Newly Diagnosed Multiple Myeloma Clinical Update EHA 2010 DR. OUSSAMA JRADI.
Palumbo A et al. Proc ASH 2012;Abstract 446.
Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Multiple Myeloma Definition:
Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.
Palumbo A et al. Proc ASH 2014;Abstract 175.
Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.
1.Defining Plasma cell disorders/Multiple Myeloma 2.Identification of different plasma cell disorders. 3.Diagnosis and workup for plasma cell disorders/Multiple.
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.
Continued Overall Survival Benefit After 5 Years’ Follow-Up with Bortezomib-Melphalan-Prednisone (VMP) versus Melphalan-Prednisone (MP) in Patients with.
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma by Sonja Zweegman, Bronno van der Holt,
New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
Randomised phase 2 trial in Waldenstrőm's macroglobulinaemia
Palumbo A et al. Proc ASH 2012;Abstract 200.
GEM2005MAS65 Trial: Bortezomib-Based Maintenance Increases CR Rate and PFS in Elderly Patients With Newly Diagnosed Multiple Myeloma Slideset on: Mateos.
Multiple Myeloma in the Non-transplant Setting
Attal M et al. Proc ASH 2010;Abstract 310.
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
Mateos MV et al. Proc ASH 2013;Abstract 403.
Goede V et al. Proc ASH 2014;Abstract 3327.
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study by Henk M. Lokhorst, Bronno van der.
Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.
Background and update from Myeloma XI Dr John Jones
Rossi A et al. Proc ASCO 2011;Abstract 8008.
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and.
Meletios A. Dimopoulos, MD
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Antonio Palumbo, Sara.
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.
Niesvizky R et al. Proc ASH 2010;Abstract 619.
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.
Palumbo A et al. Proc ASCO 2011;Abstract 8007.
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia by Charles Koller,
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,
Fowler NH et al. Proc ASH 2011;Abstract 99.
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
Multiple Myeloma Overview all transplants, autologous and allogeneic (period ) N=28.887
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
Overall survival by SCT versus observation in first complete remission
Boccadoro M et al. Proc ASCO 2011;Abstract 8020.
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matthew J. Matasar, Myron S. Czuczman,
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma by Tineke Casneuf, Xu Steven.
Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence-based review  Theresa Hahn,
Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.
Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.
Stavros V. Konstantinides et al. JACC 2017;69:
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.
Overview of the treatment protocol HLH-94
Management of hematologic malignancies in older patients
Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;
Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.
by Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J
Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.
Cold agglutinin disease
Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective.
Maintenance therapies in Multiple Myeloma
Presentation transcript:

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma by Sonja Zweegman, Bronno van der Holt, Ulf-Henrik Mellqvist, Morten Salomo, Gerard M. J. Bos, Mark-David Levin, Heleen Visser-Wisselaar, Markus Hansson, Annette W. G. van der Velden, Wendy Deenik, Astrid Gruber, Juleon L. L. M. Coenen, Torben Plesner, Saskia K. Klein, Bea C. Tanis, Damian L. Szatkowski, Rolf E. Brouwer, Matthijs Westerman, M. (Rineke) B. L. Leys, Harm A. M. Sinnige, Einar Haukås, Klaas G. van der Hem, Marc F. Durian, E. (Vera) J. M. Mattijssen, Niels W. C. J. van de Donk, Marian J. P. L. Stevens-Kroef, Pieter Sonneveld, and Anders Waage Blood Volume 127(9):1109-1116 March 3, 2016 ©2016 by American Society of Hematology

CONSORT diagram. CONSORT diagram. Reasons for noneligibility for MPT-T: no measurable disease (n = 7), no plasma cells and no plasmacytomas (n = 1), creatinine clearance <30 mL/min (n = 1), amyloidosis of the heart (n = 1), creatinine clearance <30 ml/min and amyloidosis (n = 1), polyneuropathy (PNP) grade 2 (n = 1), active malignancy last 5 years (n = 1), bladder cancer (n = 1), and registered twice by mistake (n = 1); for MPR-R: no measurable disease (n = 8), eligible for HDM and autoSCT (n = 1), angina pectoris grade 3 (n = 1), PNP grade 2 (n = 1), previous malignancy last 5 years (n = 2), pancreas carcinoma at entry (n = 1), presence of melanoma lentigo 2 months before randomization (n = 1), and registered twice by mistake (n = 1). Numbers reflect the number of patients starting with treatment in rectangle 1, proceeding to cycle 4 in rectangle 2, proceeding to cycle 7 in rectangle 4, and starting maintenance in rectangle 4. The number within the rectangles shown behind “cycles” indicate the maximum number of cycles that were given to these patients, except for the last cycle within a rectangle, as the majority of these patients proceed with therapy as can be deduced from the number of patients proceeding to either cycle 4 and 7. Sonja Zweegman et al. Blood 2016;127:1109-1116 ©2016 by American Society of Hematology

PFS and overall survival of eligible patients. PFS and overall survival of eligible patients. Kaplan-Meier estimates of (A) PFS and (B) overall survival. N, number of patients; F, number of failures (ie, progression or death); D, number of deaths; ISS, International Staging System. Sonja Zweegman et al. Blood 2016;127:1109-1116 ©2016 by American Society of Hematology

Toxicity-related discontinuation of therapy. Toxicity-related discontinuation of therapy. (A) Reasons for discontinuation of therapy due to toxicity during induction. (B) Reasons for discontinuation of therapy due to toxicity during maintenance. y-axis absolute number of patients, reflecting the number of patients discontinuing therapy due to toxicity only. In MPT-T, there were 7 patients who went off protocol before maintenance due to other reasons: 1 for pulmonary hypertension, 1 for allergic reaction, 2 for toxicity, and 3 because of decision of physician. In the MPR-R arm, there were 5 patients who went off protocol before maintenance due to other reasons: 2 because of decision of physician and 3 for toxicity. In the thalidomide maintenance arm, 5 patients went off protocol due to other reasons: 2 for SPM, 1 died, and 2 because of refusal of patient and hematologic toxicity. In the lenalidomide maintenance arm, 18 patients went off protocol due to other reasons: 11 because of physician’s decision, mainly symptoms or side effects, 2 for dementia, 1 for renal failure, and 4 for SPM. Sonja Zweegman et al. Blood 2016;127:1109-1116 ©2016 by American Society of Hematology